MedPath

Neutrophile Gelatinase Associated Lipocalin Evaluation in Septic Acute Kidney Injury

Conditions
Acute Kidney Failure
Registration Number
NCT01122225
Lead Sponsor
Université Victor Segalen Bordeaux 2
Brief Summary

Acute kidney injury (AKI) is a major organ failure in septic shock. Current medical tests (serum creatinine and urea) cannot identify AKI until approximately 48 hours after it occurs. Neutrophil gelatinase-associated lipocalin (NGAL) may be able to predict ischemic AKI more effectively and faster than serum creatinine and urea levels.

The purpose of this study is to take a blood sample from patients at admission and then at 24 and 48 hours after to test their plasma for NGAL and compare the NGAL levels to their creatinine and urea levels. The investigators hypothesize that NGAL is an earlier marker to classify the kidney failure as acute tubular necrosis or pre-renal azotemia than creatinine and urea.

Detailed Description

Primary Outcome Measures:

To correlate elevated serum NGAL with the diagnosis of intrinsic acute kidney injury in septic shock

Secondary Outcome Measures :

To compare serum NGAL with serum creatinine, serum urea and urine output in septic AKI Death within the intensive care unit Death from all causes at 28 days after inclusion

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
50
Inclusion Criteria
  • Patients showing signs of infection and hypotension requiring the use of epinephrine despite of an appropriate fluid challenge.
  • 18 years of age or older
Exclusion Criteria
  • Age under 18 years
  • Prisoners or other institutionalized or vulnerable individuals
  • Participation in an interventional clinical study within the previous 30 days

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Reanimation medicale, Hopital Saint-Andre, Bordeaux University Hospital

🇫🇷

Bordeaux, Aquitaine, France

© Copyright 2025. All Rights Reserved by MedPath